Are clonazepam (Klonopin), fluoxetine, gabapentin (Neurontin), clonidine, and quetiapine (Seroquel) safe to use in patients with chronic kidney disease?

Safety of Clonazepam, Fluoxetine, Gabapentin, Clonidine, and Quetiapine in Chronic Kidney Disease

These medications can generally be used in CKD with appropriate dose adjustments and monitoring, though each requires specific considerations based on the severity of renal impairment.

Gabapentin (Neurontin)

Gabapentin requires the most significant dose adjustment in kidney disease as it is eliminated almost entirely unchanged by the kidneys 1.

• Dose reduction is mandatory in patients with reduced GFR, as gabapentin is at high risk of accumulation and toxicity 1
• Gabapentin is significantly removed by hemodialysis and requires supplemental dosing after dialysis sessions 1
• The medication was implicated in a case of fall and hip fracture when prescribed at full dose (300 mg three times daily) to a patient on peritoneal dialysis without appropriate dose adjustment 2
• Use with caution and adjust dosage in renal insufficiency (GFR <30 mL/min/1.73 m²) 3

Clonazepam (Klonopin)

Clonazepam can be used in CKD but requires careful monitoring due to metabolite accumulation 4.

• Metabolites of clonazepam are excreted by the kidneys; caution should be exercised to avoid excess accumulation 4
• Start with low doses in patients with renal impairment and observe closely, particularly in elderly patients who are more likely to have decreased renal function 4
• Diazepam and midazolam (similar benzodiazepines) require no dose adjustment in renal failure as they are metabolized in the liver 5
• Sedating drugs like benzodiazepines may cause confusion and over-sedation, especially in elderly patients with CKD 4

Fluoxetine

Fluoxetine is generally safe in kidney disease without routine dose adjustment 6.

• In depressed patients on dialysis, fluoxetine 20 mg once daily for 2 months produced steady-state plasma concentrations comparable to those in patients with normal renal function 6
• While renally excreted metabolites may accumulate in severe renal dysfunction, use of a lower or less frequent dose is not routinely necessary in renally impaired patients 6
• A 2024 study found that antidepressant initiation (including SSRIs like fluoxetine) was associated with short-term risks but not long-term adverse outcomes in CKD patients 7
• Consider lower doses of SSRIs to potentially reduce risks of upper gastrointestinal bleeding and CKD progression, though evidence is not definitive 7

Clonidine

Clonidine can be used in CKD but requires blood pressure monitoring 8.

• Clonidine is listed as a centrally acting antihypertensive that can be used in patients with kidney disease 8
• Avoid abrupt discontinuation, which may induce hypertensive crisis; clonidine must be tapered to avoid rebound hypertension 8
• The medication is generally reserved as later-line therapy due to significant CNS adverse effects, especially in older adults 8
• Monitor blood pressure carefully in CKD patients, as hypertension is a common complication 5

Quetiapine (Seroquel)

Quetiapine appears safe in kidney disease without dose adjustment based on pharmacokinetic studies 9.

• A pharmacokinetic study found no clinically significant differences in quetiapine parameters between subjects with renal impairment and healthy controls 9
• The results indicate that dosage adjustment may be unnecessary in psychotic patients with decreased renal function 9
• However, a 2024 meta-analysis found that atypical antipsychotics as a class were associated with increased risk of both acute kidney injury (RR 1.51) and chronic kidney disease (RR 1.23), with quetiapine carrying the highest risk 10
• Despite this association, quetiapine was well tolerated in the single-dose study of renally impaired subjects 9

General Principles for All Medications in CKD

Consider GFR when dosing medications cleared by the kidneys 11, 12.

• For most clinical settings, validated eGFR equations using serum creatinine are appropriate for drug dosing 11, 12
• Perform more frequent clinical observation and dose adjustment for patients with renal impairment receiving these medications 13
• Monitor for drug accumulation and toxicity, particularly with medications that have active metabolites excreted renally 12
• Perform thorough medication review periodically and at transitions of care to assess adherence, continued indication, and potential drug interactions 11, 12

Key Pitfalls to Avoid

• Never prescribe gabapentin at standard doses in patients with GFR <60 mL/min/1.73 m² without dose reduction 2, 1
• Do not abruptly discontinue clonidine due to risk of rebound hypertension 8
• Avoid combining multiple sedating agents (benzodiazepines, gabapentin, antipsychotics) without careful monitoring, as this increases fall risk and sedation 13
• Monitor elderly patients more closely as they are at higher risk for adverse effects from all these medications in the setting of CKD 4